APC 8020

Drug Profile

APC 8020

Alternative Names: APC8020; Multiple myeloma vaccine - Dendreon; Myeloma vaccine - Dendreon; Mylovenge

Latest Information Update: 22 Mar 2012

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Amyloidosis; Multiple myeloma

Most Recent Events

  • 11 Oct 2004 No development reported - Phase-I for Multiple myeloma in Japan (unspecified route)
  • 11 Oct 2004 No development reported - Phase-II for Amyloidosis in USA (unspecified route)
  • 11 Oct 2004 No development reported - Phase-II for Multiple myeloma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top